Risk & Economy » Regulation » IFRS rules: views from the top

IFRS rules: views from the top

Initial responses to IFRS have been encouraging, but there are many issues that still need to be ironed out

A KPMG report, International Financial Reporting Standards: Views on a
financial reporting revolution
, indicates that a number of issues remain to
be resolved in order to confirm the success of the IFRS project.

Based on interviews with chief financial officers, auditors, regulators,
standard setters, analysts and auditors, the report shares opinions on a range
of topics.

US convergence

Many people commented on the need for the Securities and Exchange Commission
to come to a swift conclusion on the issue of reconciliation. Sir David Tweedie,
chairman of the International Accounting Standards Board, took an optimistic
view, saying: “The SEC has said that as long as it knows and understands what we
are doing and moving towards then that will be enough. It will mean that the
reconciliation will be gone by the end of 2007 or early 2008.”

Jon Symonds, CFO of AstraZeneca, says: “The critical step is in the attitude
of the SEC. It has always taken a legalistic view – form rather than substance.
The SEC reviews, which take place in the first half of 2006, will set the tone.”

Concern over fair value

Many interviewees criticised the “creeping influence” of fair values in the
standards. Symonds says: “I do want to know where the boundaries of fair value
are. It’s just theoretical nonsense at times.” He adds: “I am very uncomfortable
about the continuous stream of papers about fair values.” Martin Cubbon, group
FD of Swire Pacific in Hong Kong, says: “Who would have thought that accountants
would finish up valuing businesses. That’s what stock markets do.”

Rules versus principles

The interviews reveal an acknowledgement of the tension between an espoused
desire for a principles-based system, while also achieving consistency. Michael
Hughes, global head of audit at KPMG, says: “Some regulators assume consistency
will come from judgements when inevitably judgements will produce an element of
inconsistency. They need to acknowledge that absolute consistency can only come
from a rules-based system.”

Consistency of interpretation

The danger of standards being interpreted differently in different regimes
was also highlighted. Robert Herz, chairman of the Financial Accounting
Standards Board in the US, argued for patience, saying: “With so many countries
adopting IFRS there are bound, for a while, to be different versions. So there
has to be patience first and then bring it to resolution within the set of
principles.”

Looking at the situation of colleagues in the financial services sector,
AstraZeneca’s Symonds says that “companies are implementing almost
incomprehensible standards”. He adds: “And because there is no body of GAAP and
no body of support, they are finding it difficult to interpret them.” Symonds
looked partly to audit firms to be more proactive in interpreting standards,
rather than everything being pushed up to the IASB’s interpretations committee
to resolve. He adds: “We need to have accountability pushed back to the CFOs to
apply judgement. Otherwise we will push judgement out of the system. That would
be a disaster.”

Narrative reporting

Narrative reporting, such as in the operating and financial review and the US
management discussion and analysis, is seen as a key way to explain complex
accounting numbers. Symonds says: “For global accounts, you can’t encapsulate
everything in the figures. You need the accounts. But you also need the notes to
the accounts and the narrative, like the OFR, or the management discussion and
analysis. You need all three. You cannot understand it without all three.”

IFRS adoption experience

Andrew Bonfield, CFO of Bristol-Myers Squibb, the US pharmaceutical and
healthcare giant, drew on his experience as a non-executive director with BOC.
He says: There has been a huge educational and training process. There have been
a lot of policy changes as a result and the impact has been quite significant.
But I am not sure there has been a huge amount of value added so far.”

AstraZeneca’s Symonds says that dealing with the company’s intellectual
property issues and patents had caused some concerns: “We spent a lot of time
getting to grips with the treatment of intangibles. It can lead to some very odd
results… We are publishing numbers which appear more complex than they really
are and which do not communicate the real underlying business.”

Share
Was this article helpful?

Leave a Reply

Subscribe to get your daily business insights